Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 /CourierPR/ -- On September 10, 2026, management from Braveheart Bio, Inc. (Nasdaq: BRVE) will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, New York. The event, scheduled from September 9 to 11, 2026, will provide an opportunity for the biopharmaceutical company to discuss its ongoing research and development of next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

Braveheart Bio’s lead product candidate, BHB-1893, is a novel oral small-molecule cardiac myosin inhibitor (CMI) designed to treat both obstructive HCM (oHCM) and non-obstructive HCM (nHCM). The company aims to improve upon existing CMIs by ensuring rapid onset, consistent therapeutic response, preservation of systolic function, prompt reversibility, and ease of titration and monitoring.

During the conference, Braveheart Bio’s executives will engage with healthcare professionals, investors, and other stakeholders to share insights into the progress of BHB-1893 and the broader therapeutic landscape for HCM. Interested parties can access a live webcast of the event through the company’s investor relations page, which can be found in the News & Events section of the Braveheart Bio website at <https://ir.braveheart.bio/>. A replay of the session will be available shortly after the conference.

Braveheart Bio, a clinical-stage biopharmaceutical company, has been focused on advancing therapies for patients with HCM and other serious cardiovascular conditions. The company’s commitment to innovation and patient care is reflected in its ongoing clinical trials and development programs.